It is well known that the EVs released by tumor cells can promote the spread and diffusion of the tumor and also counteract the immune response by inhibiting CD-positive T cells with anti-tumor functions [159] or favoring immune escape, attenuating cytotoxic CD8+ T cells through the expression of PD-L1, considered as a target for monoclonal therapy in NSCLC patients [160]. Here, CD8A is linked to neoplasm.